EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals

Noemi Kaetterer iD, Kenneth Kulmatycki iD, Prasanna Kumar Nidamarthy iD, Elizabeth McNamara, Danielle Armas, Venkateswar Jarugula, Robert Schmouder iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70361 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Noemi Kaetterer und 6 weiteren Autor:innen. Beteiligte Einrichtung: BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Long QT Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To assess cardiac and safety parameters of iptacopan (an oral, selective, reversible, small‐molecule factor B inhibitor), we conducted a phase I, single ascending dose (SAD), exposure–response study (A2107) instead of a traditional thorough QT study. Healthy participants were randomized 3:1 to receive a single, supratherapeutic, oral dose of iptacopan 400, 800, or 1200 mg, or placebo. A2107's primary objectives were to assess iptacopan's effect on Fridericia‐corrected QT interval (QTcF) in a pooled analysis with the SAD phase of the first‐in‐human X2101 study, and the safety and tolerability of supratherapeutic iptacopan doses in participants. Secondary objectives included pharmacokinetics, changes in selected electrocardiogram (ECG) parameters, and categorical changes to the QTcF, PR, and QRS intervals and heart rate (pooled analysis). Thirty‐two participants were randomized in A2107 and 56 in X2101; demographic data were similar across treatment groups. The estimated placebo‐adjusted change from Day 1 baseline in QTcF at the geometric mean maximum drug concentration was 1.61 (90% confidence intervals: 0.39 to 2.82), 1.26 (−0.42 to 2.94), and 0.84 (−1.54 to 3.22) ms for 400, 800, and 1200 mg doses, respectively. These primary results are consistent with no risk of QT prolongation at single, supratherapeutic, oral iptacopan doses; secondary ECG data support this conclusion. No deaths, serious adverse events (AEs), or AEs leading to study discontinuation were reported; iptacopan was overall well tolerated. A high systemic exposure of iptacopan was confirmed, allowing us to conclude that single, supratherapeutic, oral doses of iptacopan had no QTcF prolongation or proarrhythmic potential in healthy individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Long QT SyndromeHumansMaleElectrocardiographyFemaleAdultHealthy VolunteersAdministration, OralYoung AdultHeart RateDose-Response Relationship, DrugMiddle AgedDouble-Blind MethodAdolescentBenzoatesIndolesPiperidines

Stichwörter der Autor:innen

ECGQTc intervalexposure responsemodelingpharmacokineticsphase Isafety

Substanzen

iptacopanBenzoatesIndolesPiperidines

Autor:innen und Institutionen

  • BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Novartis BioMedical Research, Cambridge, Massachusetts, USA.
  • Novartis Healthcare Private Limited, Hyderabad, India.
  • Celerion, Tempe, Arizona, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

ORCID-Profile: Noemi Kaetterer, Kenneth Kulmatycki, Prasanna Kumar Nidamarthy, Robert Schmouder

Zitieren

APA

Kaetterer, N., Kulmatycki, K., Nidamarthy, P. K., McNamara, E., Armas, D., Jarugula, V., & Schmouder, R. (2025). Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals. Clinical and Translational Science. https://doi.org/10.1111/cts.70361

Vancouver

Kaetterer N, Kulmatycki K, Nidamarthy PK, McNamara E, Armas D, Jarugula V, et al. Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals. Clinical and Translational Science. 2025. doi:10.1111/cts.70361

BibTeX
@article{Kaetterer2025,
  author = {Kaetterer, Noemi and Kulmatycki, Kenneth and Nidamarthy, Prasanna Kumar and McNamara, Elizabeth and Armas, Danielle and Jarugula, Venkateswar and Schmouder, Robert},
  title = {Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70361}
}
Kostenlos starten →